This study is testing a new imaging agent called 99mTc-p5+14. This agent is designed to help doctors see amyloid deposits in your body, especially in the heart, using special scans (like SPECT/CT). Amyloidosis is a condition where abnormal proteins called amyloid build up in organs. Researchers want to see how 99mTc-p5+14 moves through the body in healthy volunteers and in people with AL or ATTR systemic amyloidosis. They will also compare it to another imaging agent, 99mTc-Pyrophosphate, which is already used to diagnose heart-related ATTR amyloidosis. The main goal is to understand how much radiation exposure you would receive from 99mTc-p5+14. This study is looking for up to 31 participants, including adults aged 18 and older. The current status of the study is unclear.

Study design

This is an interventional study involving up to 31 participants. It will include both healthy volunteers and patients with systemic amyloidosis.

What's involved

The study involves measurements of radiation exposure from enrollment to 8 days after the start of the study.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 8 days after enrollment to measure whole body effective dosimetry.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.